shire plc ukfounded jerseyregistered specialty biopharmaceutical company originating united kingdom operational base united states brands products included vyvanse lialda adderall xr shire acquired takeda pharmaceutical company january shire global biotechnology company focused serving people rare diseases highly specialized conditions companys products available countries across core therapeutic areas including hematology immunology neuroscience lysosomal storage disorders gastrointestinal internal medicine endocrine hereditary angioedema growing franchise oncology emerging innovative pipeline ophthalmics original corporate headquarters located basingstoke hampshire england main offices located dublin ireland united states cambridge massachusetts chicago illinois zug switzerland addition shire owns manufacturing sites lexington massachusetts social circle georgia shires headquarters lexington massachusetts integrated takedas new us headquarters relocated deerfield illinois boston area shire founded uk five entrepreneurs harry stratford dennis stephens peter moriarty geoff hall dr jim management rolf stahel shire first listed london stock exchange shires initial products calcium supplements patients seeking treat prevent osteoporosis company acquired pharmavene million order access pharmavenes drug delivery later year shire acquired richwood pharmaceutical company forming shirerichwood company acquired biochem shires next acquisition didnt come acquired transkaryotic two years later new river pharmaceuticals inc company record purchase new river shire gained access ownership vyvanse year later company acquired german company jerini million jerini focused treating hereditary reaction new taxation measures announced uk government treatment royalties patents company moved tax domicile dublin saw change company strategy company seeking expand mergers acquisitions culminating company becoming one acquisitive industry company acquired movetis belgian company focusing gastrointestinal products year later acquired regenerative medicine manufacturer advanced company acquired ferrokin biosciences million along ferrokins lead iron chelator saw company complete highest number acquisitions lotus tissue repair inc lead compound sarcode bioscience last viropharma shire changed name viropharma shire viropharma inc upon acquisition final day trading company valued billion viropharma set new company shire acquired two rare disease drug companies antifibrotic compounds million lumena company researching rare gastrointestinal hepatic compounds nps pharmaceuticals acquired billion bringing along rare disease drugs gattex final day trading nps market capitalisation billion company also acquired later year meritage pharma million foresight biotherapeutics dyax purchases bolstered shires gastrointestinal rare disease sectors phaseiiiready treatment budesonide treatment eosinophilic esophagitis well expanding companys pipeline latestage treatment candidate infectious conjunctivitis lead candidate increasing companys rare disease catalogue dyaxs portfolio plasma kallikrein inhibitors hereditary angioedema led approved drug kalbitor phase iii january company made significant purchase billion acquisition baxalta spunoff baxter previous creating largest global biotech company focused solely rare april shire agreed sell oncology business french pharmaceutical company servier june shire rejected takeover attempt abbvie abbvie offered per share billion billion july offer increased july announced abbvie would acquire shire october news broke suggesting abbvie reconsidering proposed takeover deal due changes us tax inversion october abbvies board recommended shareholders vote news sent shires share price however abbvie would subject billion breakup fee payable october merger called april reported takeda pharmaceutical company approach acquire shire days later shire announced rejected three takeda bids first bid valued business billion per shire shares paid takeda shares plus per share cash second billion per shire shares paid takeda shares plus per share cash third billion per shire shares paid takeda shares plus per share reuters also reported interest however ruled day day later takeda increased offer fourth bid per shire shares paid takeda shares plus per share cash giving total value billion april takeda submitted enhanced fifth bid april shire said recommend revised billion billion offer shareholders enhanced offer included generous cash component deal offering cash shire ordinary day glaxosmithkline ruled making form may agreement finally reached shire sold takeda billion takedas acquisition shire closed january annual revenue figures following table drawn companys preliminary july shire licensed rights investigational hunter syndrome compound armagen annual revenue figures following table drawn companys preliminary flemming Ã¸rnskov companys chief executive officer january takedas acquisition ginger gregory chief human resources officer jeffrey poulton cfo philip vickers head james bowling vacated position interim cfo aftermath collapse abbvie inversion chair shires board directors susan september shire reached million settlement us department justice alleged violations false claims act justice department alleged shire improperly marketed promoted adderall xr daytrana vyvane pentasa lialda various periods allegations included claims shire made exaggerated false statements regarding product safety promoted medications nonfda approved offlabel use marketed products unsubstantiated claims beneficial side effects including reductions criminality traffic accidents sexually transmitted infections divorce august shire reached million settlement department justice violations act regarding unlawful promotion shires product